Open AccessPrevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF–identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012–2017: A Retrospective Province-Wide Cohort Study
Author(s) -
Andre Nyandwe Hamama Bulabula,
Jenna A. Nelson,
Eric Mulume Musafiri,
Rhoderick Machekano,
Nadia A. Sam-Agudu,
Andreas H. Diacon,
Maunank Shah,
Jacob Creswell,
Grant Theron,
Robin M. Warren,
Karen R Jacobson,
Jean Paul Chirambiza,
Dieudonné Kalumuna,
Bertin C. Bisimwa,
Patrick D. M. C. Katoto,
Michel Kaswa,
Freddy Birembano,
Liliane Kitete,
Martin P. Grobusch,
Zacharie Kashongwe,
Jean B. Nachega
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciy1105
Subject(s) - medicine , sputum , interquartile range , tuberculosis , odds ratio , confidence interval , rifampicin , logistic regression , cohort , pathology
Multidrug-resistant tuberculosis (MDR-TB) jeopardizes global TB control. The prevalence and predictors of Rifampicin-resistant (RR) TB, a proxy for MDR-TB, and the treatment outcomes with standard and shortened regimens have not been assessed in post-conflict regions, such as the South Kivu province in the eastern Democratic Republic of the Congo (DRC). We aimed to fill this knowledge gap and to inform the DRC National TB Program.